AlzeCure Pharma will present new clinical data for its drug candidate ACD440 at NeuPSIG 2025, a global pain conference taking place in Berlin from 4 to 6 September.
The abstract was accepted for presentation and will be delivered by Dr Märta Segerdal, Head of Development and CMO.
ACD440 is a topical gel formulation targeting peripheral neuropathic pain. The substance, a TRPV1 antagonist, shows powerful effects especially against heat-induced pain, according to post hoc analysis from the phase 2a study. This aligns with its mechanism of action.
The drug originated in Big Pharma and was brought into AlzeCure via strategic in-licensing. It is designed to minimise systemic exposure while ensuring high local concentrations for lasting pain relief.
Dr Segerdal said: “The fact that we obtain significant analgesic effects of ACD440 in patients with peripheral neuropathic pain, despite the fact that the majority are already treated with other painkillers, demonstrates the therapeutic potential of ACD440.”
The phase 2 study results revealed both strong efficacy and good tolerability. CEO Martin Jönsson commented on the findings: “The positive results from the phase 2 study demonstrate both significant efficacy and good tolerability and support the continued development of ACD440.”
He added that the data bolsters scientific credibility and enhances partner interest amid urgent medical need and a growing opioid crisis.
Authors of the abstract also include Adriana Miclescu, Ingrid Lönnstedt, Magnus Halldin and Rolf Karlsten. The data is expected to help guide pain precision medicine and advance treatment options for patients living with chronic neuropathic pain.
